Status:
COMPLETED
Diagnostic Tools for Human African Trypanosomiasis Elimination and Clinical Trials: WP3 Post Elimination Monitoring
Lead Sponsor:
Institut de Recherche pour le Developpement
Collaborating Sponsors:
Ministry of Public Health, Democratic Republic of the Congo
Institut National de Sante Publique
Conditions:
Human African Trypanosomiasis
Sleeping Sickness
Eligibility:
All Genders
4+ years
Phase:
NA
Brief Summary
This study determines the feasibility, diagnostic performance and cost for monitoring of eliminated human African trypanosomiasis (HAT) foci using diagnostic algorithms of serological and molecular hi...
Detailed Description
In the last decade, the prevalence of Trypanosoma brucei gambiense (Tbg) human African trypanosomiasis (HAT) has fallen and HAT has been targeted for elimination. At low disease prevalence, HAT contro...
Eligibility Criteria
Inclusion
- Permanent resident of village (in low to zero prevalence HAT focus) for minimum 1 year
Exclusion
- Previously treated for HAT (irrespective of time elapsed since treatment)
- No informed consent
- \< 4 years old
Key Trial Info
Start Date :
September 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 31 2021
Estimated Enrollment :
13747 Patients enrolled
Trial Details
Trial ID
NCT04099628
Start Date
September 1 2019
End Date
January 31 2021
Last Update
April 15 2022
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
CIRDES
Bobo-Dioulasso, Burkina Faso
2
Institut Pierre Richet, Institut National de Santé Publique
Bouaké, Côte d’Ivoire
3
Programme Nationale de Lutte contre la trypanosomiase humaine Africaine
Kinshasa, Democratic Republic of the Congo